8 September 2022
Breakthrough in identifying risk of renal impairment in people with diabetes
Research published in the Future of Healthcare Journal shows that models developed by UK healthtech start-up Gendius can determine which patients with type 2 diabetes are most likely to have renal impairment, allowing healthcare systems to prioritise the highest risk patients...
8 August 2022
INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project
Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation of a novel series of SARS-CoV-2...
3 August 2022
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme
Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to...
2 August 2022
MicroBioSensor launches QUICKCHECK™ designed in partnership with Smallfry
A device that can help speed the diagnosis of peritonitis in vulnerable kidney and liver failure patients. With results 10,000x faster than current methods, this portable and rapid detection device now means that nurses can carry out an instant leukocyte count at the...
11 July 2022
iiCON to expand pipeline following Research England funding boost
The outstanding results being achieved by the Infection Innovation Consortium – iiCON – have been acknowledged today, with £1.7 million of additional funding from Research England confirmed. Led by Liverpool School of Tropical Medicine, the iiCON consortium...
15 June 2022
Monument Therapeutics announces the start of its first clinical study for novel treatment for neuroinflammation
Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been specifically created as a novel...
13 June 2022
Oxford BioTherapeutics announces research collaboration with ImmunoGen to develop novel Antibody-Drug Conjugates
• Companies to research Antibody-Drug Conjugates (ADC) to address cancers of high unmet need … • Collaboration to utilize ImmunoGen’s ADC linker-payload technology directed to targets identified by OBT … • Each company may select a number of pre-clinical programs for...
9 June 2022
Proveca enters an exclusive agreement with Mawdsley Brooks Brazil
Proveca has entered an exclusive agreement with Mawdsley Brooks Brazil, part of global pharmaceutical services provider Mawdsleys, to commercialise and distribute Sialanar® in Brazil. Under the terms of the agreement, Mawdsley Brooks Brazil will have exclusive rights to...
6 June 2022
Rinicare’s SAFE falls reduction technology granted new UK patent
SAFE has been designed to reduce the burden on overstretched clinicians and care home staff by alerting them to pending falls events. A recently published white paper projected that falls amongst older people will increase by 3.9% a year meaning an extra 110,000 older people are...
31 May 2022
Oxford BioTherapeutics to present initial positive data from Phase I trial at ASCO 2022
• Initial data from Phase 1 dose escalation part of the trial, assessing OBT076 in adult patients with advanced solid tumors, indicated that OBT076 was generally well tolerated with no dose-limiting toxicities observed; optimal dose selected at 3.0 mg/kg. • OBT076 showed...